Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial
Public ClinicalTrials.gov record NCT07579195. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Consolidative Radiation Therapy or Cystectomy After Initial Favorable Response Succeeding Enfortumab Vedotin Plus Pembrolizumab (REINFORCE)--- A Phase I/II Pilot Feasibility Trial
Study identification
- NCT ID
- NCT07579195
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- University of Washington
- Other
- Enrollment
- 12 participants
Conditions and interventions
Conditions
Interventions
- Biospecimen Collection Procedure
- Cisplatin Drug
- Computed Tomography Procedure
- Cystoscopy Procedure
- Fluorouracil Drug
- Gemcitabine Drug
- Intensity-Modulated Radiation Therapy Radiation
- Magnetic Resonance Imaging Procedure
- Mitomycin Drug
- Pelvic Lymphadenectomy Procedure
- Positron Emission Tomography Procedure
- Questionnaire Administration Other
- Radical Cystectomy Procedure
- Stereotactic Body Radiation Therapy Radiation
- Transurethral Resection of Bladder Tumor Procedure
- Volume Modulated Arc Therapy Radiation
Procedure · Drug · Radiation + 1 more
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2026
- Primary completion
- Dec 30, 2029
- Completion
- Dec 30, 2029
- Last update posted
- May 13, 2026
2026 – 2029
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07579195, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 13, 2026 · Synced May 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07579195 live on ClinicalTrials.gov.